L&G Pharma Breakthrough UCITS ETF ISIN IE00BF0H7608

 
Add to portfolio Watch Compare
 
 
 
 

Strategy of L&G Pharma Breakthrough UCITS ETF

Investment strategy

The Solactive Biotechnology Breakthrough Value index tracks companies involved in the development and manufacturing of so-called "orphan drugs". Orphan drugs are drugs that target very rare diseases.

 

Solactive Biotechnology Breakthrough Value (1)

Equity (998) World (176) Health Care (7)

Quote

EUR 8.98
Last quote
18/11/19
7.54 52 weeks low/high 9.29
52 weeks low/high
Buy Sell
 
No savings plan
 

Risk and fees of L&G Pharma Breakthrough UCITS ETF

Risk

EUR 7 m
Fund size
Fund size category

Replication

Physical (Sampling)
Legal structure ETF
Strategy risk Long-only
Fund currency USD

Currency risk

Currency unhedged
Volatility 1 year (in EUR) 18.89% Risk category
Inception Date 23 January 2018
Maximum drawdown
since inception (in USD)
-21.13%
Maximum drawdown period 13 Months

Fees

0.75% p.a.
Total expense ratio
0.04% Compare 0.98%
Compare (Equity)

Dividend/ Taxes

Distribution policy Accumulating
Distribution frequency -
Fund domicile Ireland
Tax data Bundesanzeiger

Legal structure

Fund Structure -
UCITS compliance Yes
Fund Provider Legal & General (LGIM)
Administrator BNY Mellon Fund Services (Ireland) Designated Activity Company
Investment Advisor GO ETF Management Limited
Custodian Bank BNY Mellon Trust Company (Ireland) Limited
Revision Company KPMG
Fiscal Year End 30 June
Swiss representative State Street Fondsleitung AG
Swiss paying agent State Street Bank International GmbH, München, Zweigniederlassung Zürich

Tax Status

Germany Unkown
Switzerland Unknown
Austria Unknown
UK UK Reporting
EU Savings Directive -

Replication, swap, securities lending

Indextype -
Swap counterparty -
Collateral manager
Securities lending No
Securities lending counterparty
 
 
 

Performance of L&G Pharma Breakthrough UCITS ETF

Return

1 year: 4.87%
Performance (incl. dividend)
Return in:
 
YTD 2018 2017 2016 2015
13.27% - - - -
1 month 3 months 6 months 1 year 3 years
10.50% 6.72% 6.97% 4.87% -
 

Description of L&G Pharma Breakthrough UCITS ETF

The L&G Pharma Breakthrough UCITS ETF invests in stocks with focus Health Care, World. The dividends in the fund are reinvested (accumulating).

The total expense ratio amounts to 0.75% p.a.. The fund replicates the performance of the underlying index by buying a selection of the most relevant index constituents (sampling technique). The L&G Pharma Breakthrough UCITS ETF is a very small ETF with 7m Euro assets under management. The ETF is older than 1 year and is domiciled in Ireland.
 

Look for similar ETFs

Further ETFs on the Solactive Biotechnology Breakthrough Value

L&G Pharma Breakthrough UCITS ETF
 
— All quotes are 15 minutes delayed stock exchange quotes or NAVs (=daily published by fund provider). Quotes and reference data provided by Xignite, Inc., etfinfo and justETF GmbH. Returns include dividend payments. There is no warranty for completeness, accuracy and correctness for the displayed information.
Source:ETFinfo
 

Track your ETF strategies online